No headlines found.
Globe Newswire (Tue, 2-Dec 6:50 AM ET)
ANI Pharmaceuticals Announces Board Transition
Globe Newswire (Mon, 1-Dec 6:50 AM ET)
ANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Healthcare Conference
Globe Newswire (Tue, 25-Nov 6:50 AM ET)
ANI Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - London
Globe Newswire (Tue, 11-Nov 4:05 PM ET)
ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance
Globe Newswire (Fri, 7-Nov 6:50 AM ET)
Globe Newswire (Fri, 24-Oct 6:50 AM ET)
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Ani Pharmaceuticals trades on the NASDAQ stock market under the symbol ANIP.
As of December 17, 2025, ANIP stock price climbed to $82.35 with 365,665 million shares trading.
ANIP has a beta of 0.41, meaning it tends to be less sensitive to market movements. ANIP has a correlation of 0.04 to the broad based SPY ETF.
ANIP has a market cap of $1.85 billion. This is considered a Small Cap stock.
Last quarter Ani Pharmaceuticals reported $228 million in Revenue and $2.04 earnings per share. This beat revenue expectation by $16 million and exceeded earnings estimates by $.43.
In the last 3 years, ANIP traded as high as $99.50 and as low as $36.54.
The top ETF exchange traded funds that ANIP belongs to (by Net Assets): IJR, VTI, IWM, VXF, IWO.
ANIP has outperformed the market in the last year with a price return of +46.1% while the SPY ETF gained +11.8%. However, in the short term, ANIP had mixed performance relative to the market. It has underperformed in the last 3 months, returning -15.6% vs +2.0% return in SPY. But in the last 2 weeks, ANIP shares have fared better than the market returning +0.3% compared to SPY -1.5%.
ANIP support price is $79.48 and resistance is $82.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANIP shares will trade within this expected range on the day.